On April 14, National Football League Hall of Famer and network sports analyst Lynn Swann resigned as a Transdel director
Lynn was great with transdermal formulations that minimize adverse gastrointestinal effects, but was a tad weak on pharmacokinetic sub-studies of Phase 3 trials.